Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal nebulized scopolamine for motion sickness
NCT04999449Phase 1Completed
- Sponsor
- Dartmouth Health
- Start
- Jan 2022
- Primary completion
- May 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of scopolamine in motion sickness, sponsored by Dartmouth Health. Primary endpoints: Time to maximal concentration at 180 minutes and Side effects of intranasal scopolamine at 180 minutes. Started Jan 2022; status: completed.
02
Drugs
scopolamine
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT04999449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999449.